Duloxetine — Cymbalta — is the SNRI you reach for when pain and depression coexist. Its FDA indications, taken together, are unusual in psychiatry: major depression, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. Few medications cover this breadth, and the reason duloxetine does is the dual mechanism applied to a clinically real problem.
- Class
- SNRI
- Mechanism
- Balanced SERT + NET reuptake inhibition (more balanced ratio than venlafaxine at therapeutic doses)
- Typical dose
- 30-120 mg/day (single daily dose or split)
- Half-life
- ~12 hours
- FDA indications
- MDD, GAD, diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain, stress urinary incontinence (EU only)
- Key adverse effects
- GI (early), sexual dysfunction, dry mouth, fatigue or insomnia, increased BP, hepatotoxicity (rare but serious), discontinuation syndrome
Black box: Suicidal thinking/behavior in pediatric and young adult patients
First choice when depression coexists with chronic pain — diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain. Avoid in significant hepatic dysfunction or chronic alcohol use (hepatotoxicity risk).
The pain story is the differentiator. The brain's descending pain modulation system — pathways from brainstem nuclei down to the spinal cord that act as a brake on incoming pain signals — uses serotonin and norepinephrine. SNRIs strengthen both. Duloxetine's NET/SERT ratio is balanced enough at therapeutic doses to give clinically meaningful pain effect, and the trial evidence has accumulated across multiple chronic pain syndromes.
Duloxetine is the SNRI with the strongest pain indications, reflecting balanced serotonin-norepinephrine activity across its dose range.
Mechanism note: Duloxetine's balanced dual mechanism makes it the SNRI of choice when comorbid pain accompanies depression — the analgesic and antidepressant effects come from the same prescription.
What this means at the bedside: the patient with fibromyalgia and depression often does better on duloxetine than on an SSRI plus a separate analgesic. The patient with diabetic neuropathy and depression frequently improves on both axes with a single drug. The patient with chronic low back pain and depression, where neither the pain nor the mood is dominant but both are persistent, can sometimes find a single intervention that helps both.
The pain benefit appears even in euthymic patients — patients with chronic pain and normal mood can experience analgesia from duloxetine. This is a useful fact for the patient who refuses an "antidepressant" because they don't believe they're depressed; reframing duloxetine as a centrally acting analgesic with antidepressant properties sometimes opens the door.
Side effects share the SNRI class — GI early, sexual dysfunction at therapeutic doses, sweating, modest BP elevation, discontinuation syndrome. The duloxetine-specific concern is hepatotoxicity. Rare but real cases of severe liver injury have been reported. The drug is contraindicated in chronic alcohol use and significant hepatic impairment. In patients with risk factors — fatty liver, hepatitis C, heavy alcohol history — check baseline LFTs and monitor periodically. Any clinical signs of hepatic injury (jaundice, dark urine, right upper quadrant pain, fatigue out of proportion) warrant immediate discontinuation.
Dosing: start 30 milligrams daily for a week, increase to 60 milligrams. Most patients do well at 60 milligrams once daily; some need 90 to 120 milligrams. Above 60, the additional benefit is often modest and side effects rise. Twice-daily dosing helps some patients with breakthrough symptoms but isn't usually needed.
- Cost
- Generic: ~$10-20/month. Brand Cymbalta rare.
- Generic status
- Generic since 2013 — multiple manufacturers.
- Formulary typical
- Tier 1-2 generic. PA occasionally for pain indications.
- Access friction
- Modest. For pain indications, some plans require documented failure of other agents.
Prescriber tip: Workhorse for depression + chronic pain. Counsel about hepatotoxicity risk in heavy alcohol use; some patients screen out of duloxetine on baseline LFTs.
Discontinuation syndrome is meaningful — less severe than venlafaxine because of the longer half-life, but present. Taper over weeks rather than days. The patient who runs out and stops abruptly often comes back with flu-like symptoms and dizziness they didn't expect.
When you're choosing an SNRI for a patient where the pain is part of the picture, duloxetine is usually the starting point.